LOGIN  |  REGISTER
Recursion
Viking Therapeutics

Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1

April 15, 2024 | Last Trade: US$15.72 0.03 -0.19

VAUGHAN, Ontario / Apr 15, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

Conference Call Details

Date:

 

Wednesday, May 1, 2024

   

Time:

 

8 a.m. ET

   

Webcast:

 

https://www.webcaster4.com/Webcast/Page/2883/49631

   

Participant Event Dial-in:

 

+1 (888) 506-0062 (North America)

+1 (973) 528-0011 (International)

   

Participant Access Code:     

 

357966

   

Replay Dial-in:

 

+1 (877) 481-4010 (North America)

+1 (919) 882-2331 (International)

   

Replay Passcode:

 

49631 (replay available until May 15, 2024)

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

© 2024 Bausch + Lomb.

C4 Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page